Form: 8-K

Current report filing

December 10, 2010

 

Exhibit 99.1
 


JIM JOYCE
CHAIRMAN, CEO


LD MICRO CONFERENCE
December 9, 2010
 
 

 
MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD
LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING
WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND
INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER
PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND
OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.
Forward looking statements
 
 

 
Available Conference Documents
“A Platform Technology to Address
 Bioterrorism”
 ¤ 11/18/10
Shareholder Letter
 ¤ 12/1/10
California Equity Research Initiation
 ¤ 12/8/10
 
 
 

 
WE CREATE REVOLUTIONARY
DEVICES
THAT ADDRESS INFECTIOUS
DISEASE
& CANCER
 
 

 
THE FIRST MEDICAL DEVICE TO SELECTIVELY
FILTER VIRUSES AND IMMUNOSUPPRESSIVE
PARTICLES FROM CIRCULATION
THE HEMOPURIFIER®
 
 

 
Leveraging Established
Infrastructure
 
 

 
Selectively Targets the
Removal of:
Subtractive
Therapy
 
 

 
MEDICAL DEVICE VS.
BIOLOGIC REGULATORY
PATHWAY
 
 

 
70 TREATMENT EXPERIENCES IN
HUMANS
 
 

 
SUBSTANTIAL VIRAL LOAD
REDUCTION
IN HIV AND HCV
INFECTED INDIVIDUALS
 
 

 
LEADING BROAD-
SPECTRUM
COUNTERMEASURE
AGAINST BIOTERROR &
PANDEMIC THREATS
 
 

 
NEAR-TERM
COMMERCIALIZATION
PATHWAY OVERSEAS
 
 

 
IDE ON FILE WITH THE FDA
 
 

 
GMP MANUFACTURING
ESTABLISHED THROUGH
PARTNERSHIP WITH
NEXTPHARMA TECHNOLOGIES
 
 

 
LOI SIGNED WITH MEMBRANA
FOR LARGE-SCALE
PRODUCTION
 
 

 
HEMOPURIFIER® PROVIDES A
PIPELINE INTO THREE $ MULTI-
BILLION MARKETS
 
 

 
 
 

 
OUR WILDCARD MARKET
OPPORTUNITY
 
 

 
The Most Advanced Broad-Spectrum
Countermeasure
Bioterror & Pandemic Threats
 
 

 
Virus
Collaborators
Human
Variety
Ebola
CDC / USAMRIID
YES
Dengue
NIV / WHO
YES
Lassa
SFBR
YES
West Nile
Battelle
YES
H5N1 Avian
Battelle
YES
Spanish Flu of 1918-R
Battelle
YES
2009 H1N1 Swine
Battelle
YES
Monkey pox
Battelle
NO
 
 

 
“The Hemopurifier® is the only
strategy to address the breadth of
pathogens that could be weaponized
as agents of bioterror”
         Ken Alibek
 
 

 
OUR PRIMARY MARKET
FOCUS IS…..
 
 

 
TO ACCELERATE EARLY VIRAL LOAD
REDUCTION OF HCV STANDARD OF CARE
(SOC) DRUG THERAPY
Hepatitis-C Virus (HCV)
 
 

 
IN THE ABSENCE OF DRUG
THERAPY
 
 

 
5 Day HCV Treatment Studies
 
ONE WEEK STUDY - THREE HEMOPURIFIER®
TREATMENTS
 
 

 
OUR STRATEGY IS TO
COMBINE OUR
HEMOPURIFIER® WITH HCV-
SOC
TO ACCELERATE EARLY
VIRAL DEPLETION
 
 

 
VIRAL FILTRATION HAS BEEN
PROVEN TO IMPROVE
HCV
CURE RATES!
 
 

 
Validation for Viral Filtration
Therapy
Success
%
 
 

 
An Enduring Adjunct
Opportunity 
¨ Hemopurifier® + Current SOC
¨ Hemopurifier® + Future Iterations of
 SOC
 ¤ 65 drugs in competition
 
 

 
The Hemopurifier® + HCV SOC
Study
¨ Enrollment has been initiated at the
 Medicity
¨ Up to 30 Patients
¨ Up to 6 treatments in first 3 days of SOC
¨ Clinical endpoints include:
 ¤ Immediate Virologic Response (IVR)
 ¤ Rapid Virologic Response (RVR)
 ¤ Early Virologic Response (EVR)
¨ Positive outcomes trigger
 commercialization
 
 

 
OUR HEMOPURIFIER® IS THE ONLY
TREATMENT
STRATEGY TO ADDRESS DRUG
RESISTANT
AIDS PATIENTS
Human Immunodeficiency Virus (HIV)
 
 

 
DO HIV INFECTED
INDIVIDUALS
HAVE TO DIE
WHEN THEY NO LONGER
RESPOND TO THEIR MEDS?
 
 

 
IN THE ABSENCE OF DRUG
THERAPY
 
 

 
HIV/AIDS Patient Data
92% reduction of viral load
Improved CD4+ T-cell %
30 DAY STUDY - THREE HEMOPURIFIER® TREATMENTS PER WEEK
AIDS
 
 

 
IF YOU HAVE CANCER…………
 
 

 
EXOSOMES ARE SECRETED BY
ALL TUMORS, LYMPHOMAS, &
LEUKEMIAS
 
 

 
Exosomes are
Immunosuppressive
¨ Induce Apoptosis
¨ Disrupt T-Cell Signaling
¨ Inhibit Cytokine Production
¨ Angiogenesis
¨ Metastasis 
 
 

 
Tumor-Secreted Exosomes
 
 

 
OUR HEMOPURIFIER® IS THE
SOLE THERAPEUTIC STRATEGY
TO ADDRESS
IMMUNSUPPRESSIVE EXOSOMES
 
 

 
GOAL IS TO MAXIMIZE THE
ABILITY OF THE IMMUNE
SYSTEM AND/OR OTHER
THERAPIES TO COMBAT
CANCER?
 
 

 
A Complementary Therapeutic
 
¨ Targets Benefit w/o
 ¤ Stacking additional drug
 toxicity
 ¤ Adding drug interaction risk
 
 

 
 
 

 
 
 

 
Recent Additions
to the
AEMD
Team
 
 

 
September 3rd
FABIANI & COMPANY
ENGAGED
TO REESTABLISH
BIODEFENSE & PANDEMIC
THREAT PROGRAMS
 
 

 
October 26th
MIRIAM PROVOST NAMED
 U.S. REGULATORY
 ADVISOR
 
 

 
Miriam Provost
¨ 13 Years at FDA-ODE
 ¤ Deputy Director
 ¤ Division Director
 ¤ Branch Chief
 
 

 
October 28th
ROD KENLEY NAMED
 PRESIDENT
 
 

 
Rod Kenley
¨ BAXTER
 ¤ Conceived the HomeChoice Peritoneal Dialyzer
 n International Marketing Manager
 n Director of Worldwide Product Planning
 n Director of Advanced Product Development
¨ AKSYS LTD
 ¤ Founder
 ¤ Commercialized the PHD System, the first daily
 home hemodialysis machine
¨ DEKA RESEARCH
 
 

 
The HomeChoice® Device
 
 

 
CREATE A PORTABLE
HEMOPURIFIER® TO DELIVER
IN-HOME BENEFIT
 
 

 
Selected 2011 Milestone
Targets
¨ HCV TREATMENT DATA
¨ HCV Commercialization
¨ Approval to Initiate U.S. Studies
¨ Clinical Partners Established in EU
¨ Multiple Bioterror Contract/Grant
 Submissions
¨ Cancer
 ¤ Data from multiple studies
 ¤ Disclosure of collaborative partnerships
¨ Advance Mobile/In Home Hemopurifier®
 
 

 
CREATING REVOLUTIONARY
DEVICES
THAT ADDRESS INFECTIOUS
DISEASE
& CANCER
 
 

 
JIM JOYCE
CHAIRMAN, CEO

8910 UNIVERSITY CENTER LANE
SAN DIEGO, CA. 92122

JJ@AETHLONMEDICAL.COM
858.459.7800 X301

ASSISTANT: CHARLENE OWEN
COWEN@AETHLONMEDICAL.COM
858.459.7800 X305